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Hyaluronidase facilitated subcutaneous immunoglobulin (fSCIg) is a new 
immunoglobulin product for replacement therapy in patients with primary antibody 
deficiencies (PAD). The pre-administration of recombinant human hyaluronidase 
associated with 10% immunoglobulin allowed the infusion of larger (up to 600 ml) 
amounts of immunoglobulin at a single infusion site, enabling patients to receive 
the necessary treatment in a single monthly dose. Here, we report the effectiveness 
and the tolerability of fSCIg in patients with severe PAD-related comorbidities: 
refractory autoimmune thrombocytopenia; systemic granulomatous disease; severe 
enteropathy, and Type I diabetes. We conclude that fSCIg could be a feasible option 
to improve the adherence to replacement therapy also by patients with severe PAD.
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Primary antibody deficiencies (PAD) are 
characterized by a quantitative and/or 
qualitative impairment of antibody produc-
tion. Common variable immunodeficiency 
(CVID) and X-linked agammaglobulinemia 
(XLA) are the most common symptomatic 
forms of PAD [1]. CVID includes a hetero-
geneous group of antibody deficiencies of 
unknown etiology, frequently diagnosed in 
adults, in which specific criteria could help in 
differentiating them from other inborn error 
of immunity. Across the spectrum of clini-
cal manifestations, patients are frequently 
affected by severe and recurrent infections, 
autoimmune disorders, granulomatous and 
inflammatory diseases and cancers [2]. XLA is 
inherited as an X-linked recessive trait caused 
by Bruton’s tyrosine kinase or BTK mutations 
resulting in a defective bone marrow B cell 
differentiation [3]. Improvements in aware-
ness, prompt diagnosis and the introduction 
of immunoglobulin replacement therapy 
have resulted in substantially extended life 
expectancy for patients with PAD [4–6]. 
Treatment of PAD patients requires life-long 
replacement with human polyvalent immu-
noglobulins (Ig) administered by intravenous 
(IVIg), or subcutaneous (SCIg) routes [7,8]. A 
third route is intramuscular, although this 
is uncommonly. Recently, hyaluronidase-
facilitated subcutaneous immunoglobulins 
(fSCIg) with recombinant human hyaluroni-
dase (rHuPH20) pre-administered subcuta-
neously, followed by human immunoglobu-
lin 10% infused through the same needle, 
has become available [9].
The pre-administration of rHuPH20 
increases subcutaneous tissue permeability 
and facilitates drug dispersion and absorp-
tion, enabling the monthly administration 
of large amounts of product in one site with 
consequent increased intervals between 
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administrations compared with conventional SCIg [10]. 
fSCIg are dispensed after four steps of administra-
tion with increased dosages injected at short interval 
times called ramp-up schedule. This schedule permits 
patients to become adapted to a large volumes of liquid 
administered subcutaneously. After the initial ramp-
up, fSCIg are administered at 300 to 600 mg/kg at 
3–4 week intervals.
Data have already shown a good efficacy profile 
and a low rate of adverse reactions to fSCIg allowing 
home-based administration for adequately trained 
patients [11,12]. However, few data are available on 
the efficacy and tolerability of fSCIg in patients with 
PAD-associated complicated clinical conditions such 
as enteropathy, cytopenias and granulomatous disease. 
These comorbidities require a careful personalized 
evaluation of immunoglobulin dosages and schedules 
of administration in order to improve the clinical out-
come [13]. Here, we report on five patients diagnosed 
according to the ESID/PAGID criteria, affected by 
serious PAD-related comorbidities. Clinical, immuno-
logical data, reason to start fSCIg therapy and data 
after the treatment were summarized in Table 1.
Case 1
A 58-year-old woman came to our attention after a 
long-standing history of upper respiratory tract infec-
tions and refractory idiopathic thrombocytopenia 
(ITP) treated with glucocorticoids and splenectomy. 
CVID was diagnosed based on low serum immuno-
globulin levels (IgG 82 mg/dl, IgA 25 mg/dl, IgM 47 
mg/dl) and impaired specific antibody responses, after 
exclusion of secondary hypogammaglobulinemias. The 
patient began IVIg at the dosage of 0.6 g/kg/month. 
Platelet (PLT) count increased from 30,000/mm3 to 
130,000/mm3. After 4 years, in December 2014, she 
presented with mild mucocutaneous haemorrhages 
associated with a PLT count of 53,000/mm3. Labora-
tory tests revealed normal red blood cell, reticulocyte 
and white blood cell counts and no abnormalities on 
peripheral blood smear. Anti-PLT autoantibodies were 
positive. Bone marrow biopsy showed an increase in 
megakaryocytes. Abdominal ultrasound scan dem-
onstrated the presence of residual splenic tissue. Since 
she could not tolerated an increased IVIg dosage and 
she refused to receive two divided IVIg doses, she was 
switched to fSCIg. The product was administered by a 
programmable pump without petechial hemorrhaging 
at the infusion site. We used a standardized infusion 
protocol with a velocity/dose ramp-up (as shown in 
Figure 1) and we achieved the IVIg equivalent monthly 
dose after four infusions. The patient received fSCIg 
20 g twice a month and IgG trough levels remained 
constantly above 750–850 mg/dl. After two infusions, 
the PLT values rose from 53,000/mm3 to 122,000/
mm3 and subsequently remained >80,000/mm3 for 
the following 7 months (Figure 1) without any further 
episode of mucocutaneous hemorrhage.
Case 2
A 60-year-old woman attended our clinic for recurrent 
infections and thrombocytopenia. On initial examina-
tion (December 2014) she had cutaneous and mucosal 
petechiae. Laboratory evaluation showed low PLT count 
(58,000/mm3), normal erythrocyte and leukocyte 
counts. Anti-PLT autoantibodies were u ndetectable. 
Figure 1.  Platelet count in a common variable immunodeficiency patient affected by refractory thrombocytopenia. 
After the switch to fSCIg therapy, patient had a persistent increase in platelet count. Patient started with a fSCIg 
dose of 10 g followed a week later with a 20 g dose and 2 weeks later with a 30 g dose at 3-week interval.  
fSCIg: Facilitated subcutaneous immunoglobulin.
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She had low serum Ig levels (IgG 403; IgA 
52; IgM 16 mg/dl) and impaired response to 
tetanus toxoid. After exclusion of secondary 
hypogammaglobulinemias, she was diagnosed 
with CVID. Due to the poor venous access, she 
started fSCIg as an immuno globulin replace-
ment treatment. Afterwards ramp-up schedule 
(as shown in Figure 2), fSCIg were adminis-
tered at the dosage of 20 g biweekly achiev-
ing the dosage of 0.6 g/kg/month. After the 
second infusion, PLT rose from 58,000/mm3 
to 93,000/mm3 (Figure 2) with resolution of 
petechiae. Serum IgG levels reached a protec-
tive value after two infusions (550 mg/dl), 
remaining above 800mg/dl in the subsequent 
year. No infectious episodes were documented. 
Platelet counts remained constantly >100,000/
mm3. Mild or moderate redness occurred at the 
injection site but disappeared without sequelae 
by lowering the infusion rate to 140 ml/h. No 
petechial h emorrhaging was recorded at the 
infusion site.
Case 3
A 46-year-old man was affected by CVID 
complicated by granulomatous systemic dis-
ease. He came to our attention at the age of 40 
years because of a marked reduction of serum 
levels of IgG and IgA with a clinical history of 
recurrent infections. The CVID diagnosis was 
make at the age of 27 years, but the replace-
ment therapy with IVIg was performed in an 
irregular manner in the reference hospital, 
then stopped for serious adverse reaction. After 
the first examination, in absence of replace-
ment therapy for several months, he was hos-
pitalized because he developed fever, lymph 
node enlargement, infiltrated skin lesions 
and episodes of abdominal pain. Skin biopsy 
showed granulomatous dermatitis. The com-
puted tomography showed splenomegaly and 
enlarged superficial mediastinal and abdominal 
non-confluent lymph nodes. Lymph node and 
bone marrow biopsies revealed non-necrotizing 
epithelioid granulomas. In the following years, 
renal and hepatic biopsy were also performed 
due to a progressive renal function impairment 
and to increased liver enzyme serum levels. 
Liver and kidney histology showed a small-
medium size lymphocyte infiltrate. However, 
no conclusive evidence of a lymphoprolifera-
tive disease was obtained. Oral cyclophospha-
mide was also started and continued up to a 
total dose of 9 g followed by other immuno-
998 Immunotherapy (2016) 8(9) future science group
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suppressant drugs (mycophenolate mofetil at 30 mg/
kg/day orally). After 8 months, renal and liver func-
tion improved. Despite conventional SCIg infusion 
administered at 0.7 g/kg/month, trough IgG levels 
progressively decreased to 200 mg/dl and the num-
ber of respiratory infections increased. Antibiotic pro-
phylaxis was initiated At the end of 2014, fSCIg was 
available in Italy and the patient was switched to fSCIg 
with a ramp-up protocol. After ramp-up, satisfactory 
response was documented by the increase in serum 
IgG levels from 319 to 648 mg/dl (Figure 3) and by a 
reduction of infectious episodes. Initially, the patient 
received fSCIg 25 g twice a month, then the interval 
was increase to a 3-weekly administration with a con-
sequent drop of IgG trough levels that remained con-
stantly >550 mg/dl. After 12 months, the granuloma-
tous disease caused a catastrophic multiorgan failure 
and the patient died.
Case 4
A 25-year-old man had a diagnosis of XLA compli-
cated by severe malabsorption and weight loss. His 
clinical history was characterized by recurrent episodes 
of pneumonia and chronic diarrhea. Duodenal biopsy 
showed increased count of intraepithelial lymphocytes 
(>30/100 epithelial cells) associated with severe intes-
tinal villous atrophy. Initially, a coeliac disease was 
suspected. The diagnosis of celiac disease is difficult 
in patients with PAD, due to the impossibility to use 
serological data. The presence of HLA DQ2 and DQ8 
could be helpful [14]; however, the response to a glu-
ten free diet remains the main diagnostic criteria [15]. 
The patient did not respond to a gluten-free diet so 
he was diagnosed as an duodenal villous atrophy asso-
ciated to the immunodeficiency [16]. Replacement 
therapy was challenging in that IVIg administered at 
a cumulative dose of 40 g/month (0.7 g/kg/month) 
did not achieve a satisfactory clinical and immunologi-
cal response. We increased the Ig monthly cumulative 
dose up to 50 g/month (0.8 g/kg/month) by adminis-
tering IVIg and SCIg at the same time. This allowed 
a good clinical response with IgG trough levels persis-
tently >600 mg/dl in the absence of major infections. 
However, the patient had poor compliance with SCIg 
administration due to social and family background 
disadvantage. He progressively self-reduced the cumu-
lative Ig monthly dose to 30 g with a consequent drop 
in the IgG trough levels (Figure 4A). At that time he 
had an episode of pneumonia. In December 2014, to 
reduce the number of subcutaneous Ig administration, 
and possibly improve the adherence, he started fSCIg 
according to the ramp-up protocol. After 40 g of fSCIg 
his IgG trough levels remained very low (200 mg/dl) 
and we had to introduce a single IVIg administration 
soon after the ramp-up to achieve a total a cumula-
tive monthly dose of 50 gr. This allowed for a satisfac-
tory IgG trough level and administration of monthly 
fSCIg doses. Unfortunately, the patient was again not 
adherent to the IVIg therapy and, 20 days after the last 
fSCIg administration, the IgG trough level dropped 
again to 100 mg/dl and the patient had a new episode 
of pneumonia requiring hospitalization (Figure 4B). 
Later on, the patient shifted back to IVIG at a cumu-
lative monthly dosage of 50 g/month. However, the 
Figure 2.  Platelet count in a naive common variable immunodeficiency patient affected by thrombocytopenia. 
Since the diagnosis the patient was treated with fSCIg. Platelet counts increased to 100,000/mm3 and serum IgG 
levels reached a protective value after two fSCIg administrations. Platelet counts remained constantly >100,000/
mm3 during the follow-up.  
fSCIg: Facilitated subcutaneous immunoglobulin.
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serum trough IgG levels remained below 4.0 g/l. The 
patient was encouraged to start again a combination of 
fSCIg (30 g/month) and IVIg (20 g/month), in order 
to improve the adherence and to achieve a satisfactory 
IgG trough levels (>650 mg/dl).
Case 5
A 55-year-old man had a diagnosis of CVID with a 
clinical history of bronchiectasis and chronic sinusitis 
and a diagnosis of insulin dependent diabetes since 
infancy. Thus, he had to replace both immunoglobu-
lin and insulin using a bimonthly IVIg administration 
and a continuous infusion of rapid-acting insulin by 
pump delivery. Replacement therapy with IVIg was 
efficacious and well tolerated at a monthly cumula-
tive dosage of 30 g. However, recently the placement 
of peripheral intravenous lines became extremely dif-
ficult. The patient refused conventional SCIg since he 
was on continuous insulin infusion. In January 2015 he 
switched to fSCIg; according to the ramp-up protocol, 
after three initial doses, he could reach the same dos-
age and frequency of IVIg treatment. This allowed a 
satisfactory IgG trough level 4 months after the initial 
dose at the time of the monthly fSCIg a dministration 
(Figure 5).
Discussion
Ig replacement is the standard therapy for PAD, 
which aims to replace the missing antibodies and to 
prevent recurrent infections. Replacement therapy 
generally encompasses the use of 400–600 mg/kg 
of human immunoglobulin administered intrave-
nously every 3 or 4 weeks or subcutaneously daily 
to every 2 weeks. The optimal choice of timing and 
administration route is indeed an important determi-
nant of the adherence to IgG long-term therapy and 
patient outcomes. Research into individualized medi-
cine and personalized health presents methodologi-
cal challenges. In PAD, different options have been 
explored to establish how we should individualize Ig 
replacement therapy. As with many interventions, 
there may be specific subgroups of patients who are 
more likely to benefit from treatment with higher or 
lower dosages of immunoglobulins. Moreover, there 
are PAD patients who did not achieve a satisfac-
tory efficacy, despite immunoglobulin replacement 
administered according to the international guide-
lines [13]. Recently, the introduction of hyaluroni-
dase fSCIg has allowed the infusion of larger (up to 
600 ml) amounts of Ig at a single infusion site. This 
new product might enable the patient to receive the 
replacement treatment with a single monthly dose, 
with a possible improvement in adherence and quality 
of life [9,17–19]. Here, we reported on a series of PAD 
patients with serious comorbidities poorly responsive 
to conventional IVIg or SCIg who shifted to replace-
ment with fSCIg. All remained free from severe infec-
tions with the exception of an XLA patient who suf-
fered from critical malabsorption. Interesting, for this 
patient only a high IgG cumulative monthly dosage 
Figure 3.  IgG serum levels in a common variable immunodeficiency patient suffering from systemic 
granulomatous disease and recurrent severe infections who previously failed several conventional SCIg 
treatment schedules. In December 2014, the patient switched to fSCIg and reached protective serum Ig levels. 
During the follow-up, the patient remained infection free. However, the granulomatous disease progressively led 
to a catastrophic multiorgan failure and the patient died. 
fSCIg: Facilitated subcutaneous immunoglobulin.
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administered using a combination of fSCIg and IVIg 
resulted in a clinical and immunological improve-
ment. Various hypotheses can be evoked to explain 
this effect of fSCIg replacement therapy in a patient 
with a severe protein losing enteropathy: first, the use 
of fSCIg (and IVIg) improved the patient’s adher-
ence; second, trough levels increased due to the new 
pharmacokinetics. In fact, fSCIg administered sub-
cutaneously are slowly absorbed and redistributed, 
with a probably low dispersion. An improvement of 
IgG trough levels and a reduction of infectious epi-
sodes was also documented in the patient affected 
by a life-threatening critical granulomatous CVID-
associated disease. The treatment with fSCIg had a 
good tolerability. Our patients did not have systemic 
side effects or complain of any discomfort from treat-
ment. Moreover, fSCIg therapy was well tolerated 
also in the patient with diabetes who was under an 
additional long-life continuous treatment with insu-
lin and in the two patients with thrombocytopenia, 
who did not report any local hemorrhagic manifesta-
tions at the infusion site. In these two patients, fSCIg 
improved the refractory thrombocytopenia. Accord-
ing to Seidel [20], thrombocytopenia in PAD could 
be a primary feature of the immunodeficiency, being 
autoantibody-mediated and/or cell-mediated. At this 
regard, we speculate about the possible immuno-
modulatory role of fSCIg which can reflect that of 
IVIg, even if fSCIg has a slightly lower serum Ig level 
peak as compared with IVIg. In immune-mediated 
Figure 4.  IgG serum levels in a X-Linked agammaglobulinemia patient affected by duodenal villous atrophy 
during IVIg and conventional SCIg treatment (A) and IVIg plus fSCIg treatment (B). Before 2014, the patient had 
several pneumonia episodes requiring hospitalization. He reached protective IgG levels only by a combination 
of IVIg and SCIg, with a cumulative monthly dose of 50 g/month. Because of his low adherence to therapy, the 
patient switched to a combination of IVIg and fSCIg at the same monthly dosage. 
fSCIg: Facilitated subcutaneous immunoglobulin.; IVIg: Intravenous immunoglobulin.
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diseases, several mechanisms of action have been sug-
gested to explain the molecular and cellular pathways 
that are involved in IVIg-mediated immunomodula-
tion, depending on the nature of the disease [21–25]. 
It is also probable that more than one mechanism is 
responsible for the beneficial effect of IVIg in certain 
diseases. Recently conventional SCIg have been suc-
cessfully employed in immune-mediated diseases such 
as chronic inflammatory demyelinating neuropathy, 
multifocal motor neuropathy and idiopathic inflam-
matory myopathies [26]. The immunodulatory mech-
anism of action of SCIg (and of facilitated SCIg) is 
not completely understood. We can speculate that an 
alternative molecular target to IVIg may be involved 
due to the subcutaneous route of administration.
Although more data and a longer follow-up period 
are necessary to verify the effectiveness of fSCIg in 
PAD patients affected by serious comorbidities, our 
preliminary findings document a good tolerance of 
fSCIg. For these patients, fSCIg could be a feasible 
option to improve adherence to therapy and possibly 
improve PAD-related comorbidities and quality of life.
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Executive Summary
•	 The administration of facilitated subcutaneous immunoglobulin (fSCIg) was effective in maintaining 
adequate serum IgG levels and in reducing the infections in a series of five patients with common variable 
immunodeficiency.
•	 fSCIg might have an immunomodulatory potential as seen in two patients who improved their common 
variable immunodeficiency associated immune-mediated thrombocytopenia.
•	 The administration of fSCIg was well tolerated and patients reported no relevant side effects.
Figure 5.  IgG serum levels in a common variable immunodeficiency patient affected by insulin-dependent 
diabetes on continuous insulin-replacement therapy. 
During the follow-up patient had a good adherence to therapy and maintained protective IgG serum levels. 
fSCIg: Facilitated subcutaneous immunoglobulin.
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